Latest news with #Odomzo
New Indian Express
3 days ago
- Business
- New Indian Express
Sun Pharma's Checkpoint buy: Why it's a strategic fit in the new SPIL focus
CHENNAI: India's largest drug maker, Sun Pharmaceutical Industries, has completed its acquisition of US-based Checkpoint Therapeutics for approximately $355 million. This strategic move significantly strengthens Sun Pharma's oncology and dermatology portfolio, aligning with its focus on high-value specialty therapies. Despite the long-term strategic value, the market reaction on Friday surprised many, as Sun Pharma's share price fell by 1.46% at the close of the week's trading. This dip may have been driven by immediate concerns, including regulatory issues at a key manufacturing facility and the company's cautious financial guidance. Investors are closely monitoring developments—particularly the US FDA's observations regarding Sun Pharma's Dahej facility. The company's financial performance in the coming quarters will also be under scrutiny as stakeholders assess the potential impact on its stock trajectory. Strategic Rationale and Synergies of the Checkpoint Deal Drug industry analysts believe the Checkpoint acquisition is a major strategic gain for Sun Pharma, which has historically grown through carefully chosen, high-potential acquisitions. According to analysts at HDFC Securities, the deal aligns with Sun Pharma's capital allocation strategy to strengthen its specialty business. Checkpoint's Unloxcyt—a novel skin cancer drug—will serve as a complementary addition to its oncology portfolio. In the post-Q4 earnings call, Chairman and Managing Director Dilip Shanghvi reiterated the company's commitment to expanding its specialty business. Sun Pharma's specialty and innovative therapeutics division currently focuses on dermatology, ophthalmology, and oncology. Unloxcyt will complement existing products such as Odomzo (sonidegib) and Yonsa (abiraterone acetate)—both approved in the US—Nidlegy (awaiting approval in the EU), and the recently acquired Fibromun (in Phase III trials). Other specialty molecules in development, including Ilumya (for psoriatic arthritis), GL0034 (obesity), MM-II (osteoarthritis), SCD-044 (atopic dermatitis/psoriasis), and Fibromun (for soft tissue sarcoma/glioblastoma), offer long-term growth potential. According to analysts, the Checkpoint acquisition is strategically significant for four key reasons:
&w=3840&q=100)
Business Standard
20-05-2025
- Business
- Business Standard
Sun Pharma Q4 preview: Analysts expect 18% jump in profit; check details
Sun Pharma Q4 results preview: Pharmaceutical major Sun Pharmaceutical Industries is expected to report decent set of numbers in the March 2025 quarter (Q4 FY25) on the back of continued expansion of speciality products like Odomzo and Ilumya in emerging markets (EM) and the rest of the world (ROW). In addition, new product launches are expected to boost the company's leadership in branded generics in India, according to analysts. Sun Pharma Q4 results 2025 date: The company is scheduled to announce its fourth quarter results on Thursday, May 22, 2025. Sun Pharma Q4 results: Profit expectations Sun Pharma Q4 results: Revenue expectations The pharma major's revenue for the quarter under review is expected to increase 13 per cent to ₹13,550 crore, on average, as compared to ₹11,982.9 crore in the corresponding quarter of the previous fiscal. On a sequential basis, revenue is expected to remain flat compared to ₹13,675 crore in the December 2024 quarter. Brokerages expected the company's earnings before interest, tax, depreciation and amortisation (Ebitda) to increase nearly 20.5 per cent to ₹3,726 crore in Q4FY25 compared to ₹3,091.5 crore in the year-ago period. Here's how analysts expect Sun Pharma to perform in Q4 FY25: Phillip Capital: Analysts at Phillip Capital expect Sun Pharma to report 14 per cent growth in sales on account of sustained double-digit growth in US speciality, ramp up in gRevlimid sales and sustained growth in domestic formulations. The company's margins are likely to stand at 28 per cent, led by sustained momentum in Revlimid sales, US speciality business and domestic formulation, resulting in a 25 per cent increase in Ebitda. With stable operating performance, earnings are likely to grow 22 per cent on a yearly basis but decline sequentially. Nirmal Bang Institutional Equities: The domestic brokerage firm expects Sun Pharma's Q4 revenue to increase 15 per cent Y-o-Y, on the back of continuous growth in Winlevi, Ilumya, and Cequa along with ramp up of gRevlimid. The company's India business is likely to grow 11 per cent Y-o-Y, led by gains across segments. 'ROW and EMs should expand 20 per cent and 35 per cent, respectively, owing to the launch of Ilumya in China and other new products. Ebitda margin is expected to remain strong at 27.2 per cent,' the brokerage said. HDFC Securities: Analysts at HDFC Securities expect the pharma major's US generic business to grow sequentially, led by gRevlimid sales and steady Taro sales. Speciality sales are also expected to grow 10 per cent Y-o-Y. Steady gross margin and costs will lead to Ebitda margin expansion.
